130
Views
2
CrossRef citations to date
0
Altmetric
Original Research

The Impact of Glucocorticoid Therapy on Guideline-Directed Medical Treatment Titration in Patients Hospitalized for Heart Failure with Low Blood Pressure: A Retrospective Study

, , , , , , & show all
Pages 6693-6701 | Published online: 12 Oct 2021

References

  • Peri-Okonny PA, Mi X, Khariton Y, et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF registry. JACC Heart Fail. 2019;7(4):350–358.
  • Gheorghiade M, Vaduganathan M, Ambrosy A, et al. Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. Heart Fail Rev. 2013;18(2):107–122.
  • Verbrugge FH, Dupont M, Finucan M, et al. Response and tolerance to oral vasodilator up-titration after intravenous vasodilator therapy in advanced decompensated heart failure. Eur J Heart Fail. 2015;17(9):956–963.
  • Greene SJ, Fonarow GC, DeVore AD, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(19):2365–2383.
  • Henning RJ, Becker H, Vincent JL, Thijs L, Kalter E, Weil MH. Use of methylprednisolone in patients following acute myocardial infarction. Hemodynamic and metabolic effects. Chest. 1981;79(2):186–194.
  • Liakopoulos OJ, Schmitto JD, Kazmaier S, et al. Cardiopulmonary and systemic effects of methylprednisolone in patients undergoing cardiac surgery. Ann Thorac Surg. 2007;84(1):110–118;discussion 118–119.
  • Writing Committee M, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Card iology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.
  • Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the Ameri can College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–1852.
  • Liu C, Liu K. Effects of glucocorticoids in potentiating diuresis in heart failure patients with diuretic resistance. J Card Fail. 2014;20(9):625–629.
  • Massari F, Mastropasqua F, Iacoviello M, Nuzzolese V, Torres D, Parrinello G. The glucocorticoid in acute decompensated heart failure: dr Jekyll or Mr Hyde? Am J Emerg Med. 2012;30(3):517e515–510.
  • Miro O, Takagi K, Gayat E, et al. CORT-AHF study: effect on outcomes of systemic corticosteroid therapy during early management acute heart failure. JACC Heart Fail. 2019;7(10):834–845.
  • Landínez R, Romero M, Maurice E. Efectos de la prednisona sobre la función renal a corto plazo en pacientes con insuficiencia cardíaca descompensada. [Effect of prednisone on short-term renal function in patients with decompensated heart failure]. Venezolana de Medicina Interna. 2014;30:176–182. Spanish.
  • Raymond R, Guindy R, Gomaa Y, Estafanos H. Effect of prednisone on refractory decompensated congestive heart failure. Eur J Heart Fail. 2014;16:263.
  • Liu C, Chen Y, Kang Y, et al. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure. J Pharmacol Exp Ther. 2011;339(1):203–209.
  • Liu C, Ge N, Zhai JL, Zhang JX. Dexamethasone-induced diuresis is associated with inhibition of the renin-angiotensin-aldosterone system in rats. Kaohsiung J Med Sci. 2016;32(12):614–619.
  • Liu C, Liu G, Zhou C, Ji Z, Zhen Y, Liu K. Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance. Can J Cardiol. 2007;23(11):865–868.
  • Regolisti G, Antoniotti R, Pastorini G, Fani F, Fiaccadori E. Management of congestion and diuretic resistance in heart failure. Nephrol Point Care. 2016;2(1):e73–e87.
  • Orvin NJ, Beavers JC, Russell SD. Acute diuretic-sparing effects of Sacubitril-Valsartan: staying in the loop. J Pharm Pract. 2021;8971900211010680. doi:10.1177/0871900211010680
  • Javidgonbadi D, Andersson B, Abdon NJ, Schaufelberger M, Östman-smith I. Factors influencing long-term heart failure mortality in patients with obstructive hypertrophic cardiomyopathy in Western Sweden: probable dose-related protection from beta-blocker therapy. Open Heart. 2019;6(1):e000963.
  • Moulder JE, Cohen EP, Fish BL. Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors. Int J Radiat Biol. 2014;90(9):762–768.
  • Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–e161.
  • Bozkurt B. Response to Ryan and Parwani: heart failure patients with low blood pressure: how should we manage neurohormonal blocking drugs? Circ Heart Fail. 2012;5(6):820–821.
  • Driscoll A, Srivastava P, Toia D, Gibcus J, Hare DL. A nurse-led up-titration clinic improves chronic heart failure optimization of beta-adrenergic receptor blocking therapy - a randomized controlled trial. BMC Res Notes. 2014;9:7.
  • Poortvliet RK, Blom JW, de Craen AJ, et al. Low blood pressure predicts increased mortality in very old age even without heart failure: the Leiden 85-plus Study. Eur J Heart Fail. 2013;15(5):528–533.
  • Oakley RH, Cruz-Topete D, He BO, et al. Cardiomyocyte glucocorticoid and mineralocorticoid receptors directly and antagonistically regulate heart disease in mice. Sci Signal. 2019;4(1945–0877):577–594.
  • Rog-Zielinska EA, Thomson A, Kenyon CJ, et al. Glucocorticoid receptor is required for foetal heart maturation. Hum Mol Genet. 2013;22(16):3269–3282.
  • Tecklenberg PL, Mullin EM, Stinson EB, Morrow AG. The effects of massive doses of methylprednisolone on myocardial contractility and peripheral vascular resistance. Am Heart J. 1973;85(2):216–226.
  • Jain P, Armando I, Juorio AV, Barden N, Benicky J, Saavedra JM. Decreased hypothalamic and adrenal angiotensin II receptor expression and adrenomedullary catecholamines in transgenic mice with impaired glucocorticoid receptor function. Neuroendocrinology. 2004;80(3):171–180.
  • Nishimura H, Yoshikawa T, Kobayashi N, et al. Effects of methylprednisolone on hemodynamics and beta-adrenergic receptor signaling in rabbits with acute left ventricular failure. Heart Vessels. 1997;12(2):84–91.
  • Zhu X, Huang Y, Li S, et al. Glucocorticoids reverse diluted hyponatremia through inhibiting arginine vasopressin pathway in heart failure rats. J Am Heart Assoc. 2020;9(10):e014950.
  • Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002;8(5):473–479.
  • Liu B, Zhang TN, Knight JK, Goodwin JE. The glucocorticoid receptor in cardiovascular health and disease. Cells. 2019;8:10.
  • Matteo RD, May CN. Glucocorticoid-induced renal vasodilatation is mediated by a direct renal action involving nitric oxide. AM J Physiol. 1997;273(6):R1972–R1979.
  • Lee SR, Kim HK, Youm JB, et al. Non-genomic effect of glucocorticoids on cardiovascular system. Pflugers Arch. 2012;464(6):549–559.
  • Smets PM, Lefebvre HP, Aresu L, et al. Renal function and morphology in aged Beagle dogs before and after hydrocortisone administration. PLoS One. 2012;7(2):e31702.
  • Gardner DG, Hane S, Trachewsky D, Schenk D, Baxter JD. Atrial natriuretic peptide mRNA is regulated by glucocorticoids invivo. Biochem Biophys Res Commun. 1986;139(3):1047–1054.
  • Gardner DG, Gertz BJ, Deschepper CF, Kim DY. Gene for the rat atrial natriuretic peptide is regulated by glucocorticoids in vitro. J Clin Invest. 1988;82(4):1275–1281.
  • Damjancic P, Vierhapper H. Permissive action of glucocorticoid substitution therapy on the effects of Atrial Natriuretic Peptide (hANP) in patients with adrenocortical insufficiency. Exp Clin Endocrinol Diabetes. 1990;95:315–321.
  • Liu C, Guan J, Kang Y, et al. Inhibition of dehydration-induced water intake by glucocorticoids is associated with activation of hypothalamic natriuretic peptide receptor-A in rat. PLoS One. 2010;5(12):e15607.
  • Erkut ZA, Pool C, Swaab DF. Glucocorticoids suppress corticotropin-releasing hormone and vasopressin expression in human hypothalamic neurons. J Clin Endocrinol Metab. 1998;83(6):2066–2073.
  • Liu RY, Unmehopa UA, Zhou JN, Swaab DF. Glucocorticoids suppress vasopressin gene expression in human suprachiasmatic nucleus. J Steroid Biochem Mol Biol. 2006;98(4–5):248–253.
  • Greenwood M, Greenwood MP, Mecawi AS, et al. Transcription factor CREB3L1 mediates cAMP and glucocorticoid regulation of arginine vasopressin gene transcription in the rat hypothalamus. Mol Brain. 2015;8(1):68.
  • Tokudome S, Sano M, Shinmura K, et al. Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis. J Clin Invest. 2009;119(6):1477–1488.
  • Gong R, Latif S, Morris DJ, Brem AS. Co-localization of glucocorticoid metabolizing and prostaglandin synthesizing enzymes in rat kidney and liver. Life Sci. 2008;83(21–22):725–731.
  • Butts KA, Phillips AG. Glucocorticoid receptors in the prefrontal cortex regulate dopamine efflux to stress via descending glutamatergic feedback to the ventral tegmental area. Int J Neuropsychopharmacol. 2013;16(8):1799–1807.
  • Adcock IM, Mumby S. Glucocorticoids. Handb Exp Pharmacol. 2017;237:171–196.